Samuraciclib
- Generic Name
- Samuraciclib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H30N6O
- CAS Number
- 1805833-75-3
- Unique Ingredient Identifier
- 46D4HS9ODA
- Background
Samuraciclib is under investigation in clinical trial NCT03363893 (Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies).
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Phase 1
Recruiting
- Conditions
- Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 510
- Registration Number
- NCT04802759
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇮🇱Rabin MC, Petach Tikva, Israel
🇮🇱Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath